Concourse Financial Group Securities, Inc. Bei Gene, Ltd. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$143.93 - $224.51 $431 - $673	-3 Closed	0 $0
Q2 2023 Aug 10, 2023	BUY	$178.3 - $266.78 $534 - $800	3 New	3 $0
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $1,077 - $1,372	-5 Closed	0 $0
Q3 2022 Nov 15, 2022	SELL	$131.8 - $202.24 $395 - $606	-3 Reduced 37.5%	5 $1,000
Q2 2022 Aug 09, 2022	SELL	$121.11 - $216.05 $121 - $216	-1 Reduced 11.11%	8 $1,000
Q1 2022 May 09, 2022	BUY	$146.52 - $269.56 $732 - $1,347	5 Added 125.0%	9 $2,000
Q4 2021 Feb 07, 2022	BUY	$248.56 - $389.34 $497 - $778	2 Added 100.0%	4 $1,000
Q1 2021 May 13, 2021	BUY	$260.64 - $382.12 $521 - $764	2 New	2 $1,000
Q4 2020 Feb 02, 2021	SELL	$221.31 - $316.61 $3,540 - $5,065	-16 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $945 - $1,432	5 Added 45.45%	16 $5,000
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $1,273 - $2,291	11 New	11 $2,000
Q3 2019 Nov 13, 2019	SELL	$120.61 - $148.29 $1,326 - $1,631	-11 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $683 - $881	-6 Reduced 35.29%	11 $1,000
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $736 - $910	-6 Reduced 26.09%	17 $2,000
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $3,510 - $4,362	23 New	23 $4,000

Others Institutions Holding BGNE

# of Institutions

250

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$2.01 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.23 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$986 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$948 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$706 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account